Court Favors Merck in Diabetes Patent Lawsuit Against Viatris
September 22 2022 - 7:38AM
Dow Jones News
By Sabela Ojea
Merck & Co. said Thursday that a West Virginia district
court ruled in favor of the company in a two-patent infringement
suit against Viatris Inc.
The company said that the case was related to the sitagliptin
medication, which is mainly sold under the brand names Januvia and
Janumet to treat type 2 diabetes.
The federal court found both Merck's patents involved on the
case were valid and infringed, Merck said, noting that the decision
is still subject to appeal.
Merck had filed infringement actions against Viatris under two
patents, for which Viatris alleged non-infringement and, or
invalidity, it said.
Viatris is seeking U.S. Food and Drug Administration approval to
market generic versions of Januvia and Janumet in the U.S., Merck
said.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
September 22, 2022 07:23 ET (11:23 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024